CATALYTAC Trademark

Serial Number: 98840485

CATALYTAC is a trademark filed by Lycia Therapeutics, Inc. on November 6, 2024. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently pending registration.

Trademark Classes

Class 5 - Pharmaceuticals

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Class 42 - Computer & Scientific

Scientific and technological services; industrial analysis and research services

Class 44 - Medical Services

Medical services; veterinary services; hygienic and beauty care for human beings or animals

Owner Contact Info

Lycia Therapeutics, Inc. (4 trademarks)

400 East Jamie Ct., Suite 200
South San Francisco, CA 94080

Entity Type: 03

Legal Representation

Attorney of Record

Connie L. Ellerbach

1,390 trademarks filed View all →

Correspondence Address

Connie L. Ellerbach Fenwick & West LLP

801 California Street

Silicon Valley Center

Mountain View, CA 94041

United States

Trademark Details

Filing Date

November 6, 2024

Registration Date

Not Registered

Goods & Services

Providing medical information; Providing medical information via a website; Medical services; Medical diagnostic testing, medical clinics, medical screenings, medical examinations and medical treatment services; Provision of pharmaceutical information; Pharmaceutical services, consultations and advice

Research and development services in the field of pharmaceuticals; drug discovery services

Pharmaceutical preparations comprising small molecules and antibodies for degrading disease-causing cellular proteins for treatment of cancer, autoimmune diseases, immunologic-based diseases, neurological diseases, and other human diseases; Pharmaceutical preparations for the prevention and treatment of cancer, autoimmune diseases, immunologic-based diseases, neurological diseases, and other human diseases; Biological preparations for the prevention and treatment of cancer, autoimmune diseases, immunologic-based diseases, neurological diseases, and other human diseases; Gene therapy products, namely, biological preparations for the treatment of cancer, autoimmune diseases, immunologic-based diseases, neurological diseases, and other human diseases; Pharmaceutical preparations for use in gene therapy; Biological preparations for use in gene therapy; Viruses for therapeutic purposes, namely, for gene therapy and antivirals